Latigo Could Benefit From Vertex's Pain Drug Market Work
Latigo Biotherapeutics is viewed as undervalued after its IPO, with onzotrigine showing stronger efficacy than Vertex's Journavx for acute pain. The company can build on Vertex's market development, has Phase 2 data suitable for pivotal use, and is funded through 2029. Its Phase 3 bunionectomy trial is the main binary catalyst, while the market gives little credit to LTG-321 and LTG-418 despite a Phase 2 readout for LTG-321 expected in 2027.
Latigo Biotherapeutics, trading as LTGO, went public in August and has since been viewed as undervalued relative to its IPO. Onzotrigine is being developed for acute pain and has shown stronger efficacy than Vertex’s Journavx in that setting.
The company’s Phase 2 data are suitable for pivotal use, and its funding extends through 2029. A Phase 3 bunionectomy study is the main binary catalyst. Investors currently assign limited value to LTG-321 and LTG-418; LTG-321 is expected to report Phase 2 data in 2027.
If onzotrigine succeeds in Phase 3, patients with acute pain could gain another non-opioid treatment option, and clinicians may have more choices for managing post-surgical pain. Hospitals, insurers, and patients could be affected by pricing, access, and adoption decisions. Latigo’s trial result may also influence investors, employees, and the broader biotech sector’s interest in NaV1.8 pain programs. These effects remain uncertain until data arrive.